Monika Katko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Monika Katko has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Endre Vezekenyi Nagy
Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
9 shared publications - Erika Galgoczi
Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
7 shared publications - Bernadett Ujhelyi
Department of Ophthalmology, Faculty of Medicine, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
6 shared publications - Eszter Berta
Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
5 shared publications - György Paragh
Department of Dermatology Roswell Park Comprehensive Cancer Center Buffalo New York USA
4 shared publications - Mariann Harangi
Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
4 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 2128
Effect of Prostaglandin Analogues on Hyaluronan Production of Orbital Fibroblasts
Background: In thyroid eye disease (TED) pathogenesis, a major contributor is hyaluronan (HA) overproduction by orbital fibroblasts (OF). TED patients often receive prostaglandin analogues (PGA) for elevated intraocular pressure. Their direct effects on OFs, however, remain unclear. Methods: OFs were established from connective tissues obtained from TED patients (n = 4) and non-TED controls (n = 4) during orbital surgeries. HA levels in primary OF culture media, and in the OFs’ pericellular coat, were measured by ELISA. Cultures were performed with or without platelet-derived growth factor BB (PDGF-BB) stimulation, and treated for 72 h with 40 µM prostaglandin F2α (PGF2α), latanoprost, bimatoprost or tafluprost. mRNA expressions of HA synthases (HAS1, HAS2, HAS3) and HA-degrading enzymes (HYAL1, HYAL2, CEMIP) were quantified by RT-PCR. Proliferation and metabolic activity were analysed using BrdU incorporation and MTT assays. Results: PGF2α and each PGA reduced HA levels in the pericellular coat (p < 0.001), while only PGAs reduced HA concentration in the culture medium. Tafluprost and latanoprost suppressed PDGF-BB-stimulated HA synthesis to or below unstimulated levels, respectively (p < 0.001). Latanoprost markedly decreased HAS2 mRNA expression (p < 0.001), even under PDGF-BB stimulation (p < 0.001). PGF2α and each PGA increased CEMIP mRNA expression (p < 0.001). Latanoprost decreased fibroblast proliferation and metabolic activity with and without PDGF-BB stimulation (p < 0.05). Conclusions: These in vitro findings suggest that PGAs modulate HA turnover in orbital fibroblasts through reduced HA synthesis and potentially enhanced degradation. While these observations are confined to cultured cells, they offer a hypothesis for potential clinical relevance in TED, which requires further in vivo validation.
- 21 September 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (9) , 2128
Open AccessEffect of Prostaglandin Analogues on Hyaluronan Production of Orbital Fibroblasts
Background: In thyroid eye disease (TED) pathogenesis, a major contributor is hyaluronan (HA) overproduction by orbital fibroblasts (OF). TED patients often receive prostaglandin analogues (PGA) for elevated intraocular pressure. Their direct effects on OFs, however, remain unclear. Methods: OFs were established from connective tissues obtained from TED patients (n = 4) and non-TED controls (n = 4) during orbital surgeries. HA levels in primary OF culture media, and in the OFs’ pericellular coat, were measured by ELISA. Cultures were performed with or without platelet-derived growth factor BB (PDGF-BB) stimulation, and treated for 72 h with 40 µM prostaglandin F2α (PGF2α), latanoprost, bimatoprost or tafluprost. mRNA expressions of HA synthases (HAS1, HAS2, HAS3) and HA-degrading enzymes (HYAL1, HYAL2, CEMIP) were quantified by RT-PCR. Proliferation and metabolic activity were analysed using BrdU incorporation and MTT assays. Results: PGF2α and each PGA reduced HA levels in the pericellular coat (p < 0.001), while only PGAs reduced HA concentration in the culture medium. Tafluprost and latanoprost suppressed PDGF-BB-stimulated HA synthesis to or below unstimulated levels, respectively (p < 0.001). Latanoprost markedly decreased HAS2 mRNA expression (p < 0.001), even under PDGF-BB stimulation (p < 0.001). PGF2α and each PGA increased CEMIP mRNA expression (p < 0.001). Latanoprost decreased fibroblast proliferation and metabolic activity with and without PDGF-BB stimulation (p < 0.05). Conclusions: These in vitro findings suggest that PGAs modulate HA turnover in orbital fibroblasts through reduced HA synthesis and potentially enhanced degradation. While these observations are confined to cultured cells, they offer a hypothesis for potential clinical relevance in TED, which requires further in vivo validation.
- Open Access
The Effect of Iatrogenic Hypothyroidism on Lipoprotein Subfractions and Markers of HDL Function in Patients with Differentiated Thyroid Carcinoma
Background/Objectives: We aimed to conduct a comprehensive assessment of how transient iatrogenic hypothyroidism, induced for diagnostic purposes during the follow up of patients with differentiated thyroid cancer, impacts both quantitative and qualitative lipid parameters. Methods: Blood samples were collected during continuous levothyroxine (LT4) supplementation and after four weeks of LT4 withdrawal. In addition to thyroid hormone levels and routine lipid parameters, LDL and HDL subfractions were analyzed using polyacrylamide gel electrophoresis (Lipoprint). Furthermore, the activities of HDL-associated human paraoxonase-1 (PON1) paraoxonase and arylesterase were measured spectrophotometrically, while the levels of myeloperoxidase and apolipoprotein M (ApoM) were determined using ELISA. The activity of key regulators in HDL remodeling was measured using activity assay kits. Results: In this prospective, single-center study, a total of 52 patients were enrolled (mean age 48 ± 15 years; 13 males and 39 females). Compared to values measured during continuous LT4 supplementation, total cholesterol, HDL-C, LDL-C, ApoA1, and ApoB100 levels were significantly elevated during iatrogenic hypothyroidism (p < 0.0001 for all parameters). Differences in lipoprotein subfraction patterns were also observed: in hypothyroidism, the mean LDL particle size decreased (p = 0.0007) and the proportion of HDL subfractions shifted to the larger HDL subfractions (p < 0.0001). The paraoxonase activity and ApoM level tended to be increased (p = 0.030 and p = 0.011, respectively). Conclusions: In short-term overt hypothyroidism, opposing changes were observed: the shift toward smaller, denser LDL subfractions is considered atherogenic, whereas the increased proportion of larger HDL subfractions, the trend for higher paraoxonase activity and apoM levels can be potentially anti-atherogenic. Our findings further characterize the functional alterations of lipoproteins in hypothyroidism.
Open AccessThe Effect of Iatrogenic Hypothyroidism on Lipoprotein Subfractions and Markers of HDL Function in Patients with Differentiated Thyroid Carcinoma
Background/Objectives: We aimed to conduct a comprehensive assessment of how transient iatrogenic hypothyroidism, induced for diagnostic purposes during the follow up of patients with differentiated thyroid cancer, impacts both quantitative and qualitative lipid parameters. Methods: Blood samples were collected during continuous levothyroxine (LT4) supplementation and after four weeks of LT4 withdrawal. In addition to thyroid hormone levels and routine lipid parameters, LDL and HDL subfractions were analyzed using polyacrylamide gel electrophoresis (Lipoprint). Furthermore, the activities of HDL-associated human paraoxonase-1 (PON1) paraoxonase and arylesterase were measured spectrophotometrically, while the levels of myeloperoxidase and apolipoprotein M (ApoM) were determined using ELISA. The activity of key regulators in HDL remodeling was measured using activity assay kits. Results: In this prospective, single-center study, a total of 52 patients were enrolled (mean age 48 ± 15 years; 13 males and 39 females). Compared to values measured during continuous LT4 supplementation, total cholesterol, HDL-C, LDL-C, ApoA1, and ApoB100 levels were significantly elevated during iatrogenic hypothyroidism (p < 0.0001 for all parameters). Differences in lipoprotein subfraction patterns were also observed: in hypothyroidism, the mean LDL particle size decreased (p = 0.0007) and the proportion of HDL subfractions shifted to the larger HDL subfractions (p < 0.0001). The paraoxonase activity and ApoM level tended to be increased (p = 0.030 and p = 0.011, respectively). Conclusions: In short-term overt hypothyroidism, opposing changes were observed: the shift toward smaller, denser LDL subfractions is considered atherogenic, whereas the increased proportion of larger HDL subfractions, the trend for higher paraoxonase activity and apoM levels can be potentially anti-atherogenic. Our findings further characterize the functional alterations of lipoproteins in hypothyroidism.
- Open Access
- 22 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10293
Protective Effect of Factor XIII Intron-K G Allele on Subclinical Vascular Disease
Carotid artery intima–media thickness (cIMT), a pre-clinical vascular change that accompanies atherosclerosis is considered as a cardiovascular risk factor. Coagulation factor XIII (FXIII) stabilizes the fibrin clot and increases its resistance to fibrinolysis. Regarding FXIII Val34Leu polymorphism, the protective effect of the Leu34 allele in the presence of elevated fibrinogen levels against myocardial infarction was demonstrated. Our aim was to investigate the effect of FXIII polymorphisms on cIMT. Patients with obesity (n = 69), type 2 diabetes mellitus (T2DM) (n = 104), and age- and sex-matched healthy controls (n = 82) were enrolled. FXIII polymorphisms (Val34Leu, His95Arg, Intron-K C>G) were determined by RT-PCR with FRET detection and melting curve analysis. cIMT was determined by B-mode ultrasound. Differences in cIMT between control (median: 0.5965, IQR: 0.5115–0.6580 mm) and T2DM (median: 0.7105, IQR: 0.5948–0.7568 mm), as well as between obese (median: 0.6105, IQR: 0.5455–0.6780 mm) and diabetic groups, were found (p < 0.0001 and p = 0.003, respectively). Genotype and allele frequencies of the studied polymorphisms did not differ between subgroups. In the study group (n = 255) after adjustment for age and sex, the presence of Intron-K G allele showed a significant and independent protective effect against cIMT progression in a separate model (p = 0.005) and after adjusting for other parameters associated with cIMT (p = 0.015). FXIII Intron-K G allele provides a protective effect against subclinical vascular disease in the studied population, and this effect is independent of the presence of obesity, as well as T2DM, Leu34 allele, and fibrinogen levels.
- 22 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10293
Open AccessProtective Effect of Factor XIII Intron-K G Allele on Subclinical Vascular Disease
Carotid artery intima–media thickness (cIMT), a pre-clinical vascular change that accompanies atherosclerosis is considered as a cardiovascular risk factor. Coagulation factor XIII (FXIII) stabilizes the fibrin clot and increases its resistance to fibrinolysis. Regarding FXIII Val34Leu polymorphism, the protective effect of the Leu34 allele in the presence of elevated fibrinogen levels against myocardial infarction was demonstrated. Our aim was to investigate the effect of FXIII polymorphisms on cIMT. Patients with obesity (n = 69), type 2 diabetes mellitus (T2DM) (n = 104), and age- and sex-matched healthy controls (n = 82) were enrolled. FXIII polymorphisms (Val34Leu, His95Arg, Intron-K C>G) were determined by RT-PCR with FRET detection and melting curve analysis. cIMT was determined by B-mode ultrasound. Differences in cIMT between control (median: 0.5965, IQR: 0.5115–0.6580 mm) and T2DM (median: 0.7105, IQR: 0.5948–0.7568 mm), as well as between obese (median: 0.6105, IQR: 0.5455–0.6780 mm) and diabetic groups, were found (p < 0.0001 and p = 0.003, respectively). Genotype and allele frequencies of the studied polymorphisms did not differ between subgroups. In the study group (n = 255) after adjustment for age and sex, the presence of Intron-K G allele showed a significant and independent protective effect against cIMT progression in a separate model (p = 0.005) and after adjusting for other parameters associated with cIMT (p = 0.015). FXIII Intron-K G allele provides a protective effect against subclinical vascular disease in the studied population, and this effect is independent of the presence of obesity, as well as T2DM, Leu34 allele, and fibrinogen levels.
- Open Access
Agarose Gel Electrophoresis Reveals the Molecular Weight Distribution of Hyaluronan Produced by Orbital Fibroblasts
Thyroid eye disease (TED) is characterized by autoimmune inflammation and structural remodelling of orbital tissues, which is a consequence of the activation of orbital fibroblasts (OFs). As a result of this activation, the production of hyaluronan (HA) and the proliferation and adipocyte differentiation of OFs are enhanced. Adipogenesis leads to additional accumulation of HA. The aim of this study was to elucidate the molecular weight distribution of HA produced by OFs under basic conditions and after adipogenic stimuli. The concentration and the molecular weight distribution of HA were examined using ELISA and agarose gel electrophoresis, respectively, in TED (n = 3) and non-TED (n = 3) OF cultures. Under adipogenic stimuli, HA production is increased in OFs. In TED OF cultures, which, unlike non-TED OFs, can differentiate into adipocytes, the enhanced proportion of high-molecular-weight (HMW) HA of more than 2000 kDa is responsible for the increased HA concentration in the culture media. In non-TED OF cultures, which contain a negligible number of differentiating cells after adipogenic stimulation, the medium-molecular-weight (MMW) HA fragments from 50 to 1000 kDa also contribute to the enhanced HA content. Increased production of HMW-HA during adipocyte differentiation of TED OFs is responsible for the elevated HA content in the culture media, which may be an important contributor to both connective tissue matrix expansion and edema in the pathogenesis of TED.
Open AccessAgarose Gel Electrophoresis Reveals the Molecular Weight Distribution of Hyaluronan Produced by Orbital Fibroblasts
Thyroid eye disease (TED) is characterized by autoimmune inflammation and structural remodelling of orbital tissues, which is a consequence of the activation of orbital fibroblasts (OFs). As a result of this activation, the production of hyaluronan (HA) and the proliferation and adipocyte differentiation of OFs are enhanced. Adipogenesis leads to additional accumulation of HA. The aim of this study was to elucidate the molecular weight distribution of HA produced by OFs under basic conditions and after adipogenic stimuli. The concentration and the molecular weight distribution of HA were examined using ELISA and agarose gel electrophoresis, respectively, in TED (n = 3) and non-TED (n = 3) OF cultures. Under adipogenic stimuli, HA production is increased in OFs. In TED OF cultures, which, unlike non-TED OFs, can differentiate into adipocytes, the enhanced proportion of high-molecular-weight (HMW) HA of more than 2000 kDa is responsible for the increased HA concentration in the culture media. In non-TED OF cultures, which contain a negligible number of differentiating cells after adipogenic stimulation, the medium-molecular-weight (MMW) HA fragments from 50 to 1000 kDa also contribute to the enhanced HA content. Increased production of HMW-HA during adipocyte differentiation of TED OFs is responsible for the elevated HA content in the culture media, which may be an important contributor to both connective tissue matrix expansion and edema in the pathogenesis of TED.
- Open Access
- 11 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 438
Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy
Background/Objectives: Type 2 diabetes mellitus (T2DM) and its macro- and microvascular complications are major health concerns with multiple factors, like advanced end glycation products (AGEs), in the background. AGEs induce long-lasting functional modification of the proteins and collagen in the vascular wall and nerve tissue. We investigated the effect of alpha-lipoic acid (ALA) treatment on AGEs, soluble AGE receptor (sRAGE), the AGE/sRAGE ratio, and the parameters of endothelial dysfunction and their correlations. Methods: In our 6-month intervention study, 54 T2DM patients with neuropathy treated according to the actual therapeutic guidelines with unchanged oral antidiabetic drugs were included and treated by daily oral administration of 600 mg ALA. A total of 24 gender and age-matched T2DM patients without neuropathy served as controls. Results: In our work, we first demonstrated the attenuating effect of alpha lipoic acid therapy on AGEs in humans (11.89 (9.44–12.88) to 10.95 (9.81–12.82) AU/μg (p = 0.017)). sRAGE levels or the AGEs/sRAGE ratio were not affected by ALA treatment or by the presence of neuropathy. We found a correlation between the changes of AGEs and the improvement of current perception threshold and progranulin levels, and an inverse correlation with the change of asymmetric dimethylarginine. Conclusions: According to our results, ALA decreases AGEs, which may contribute to the clinically well-known beneficial effect in diabetic neuropathy and improvement of endothelial function.
- 11 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 438
Open AccessAlpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy
Background/Objectives: Type 2 diabetes mellitus (T2DM) and its macro- and microvascular complications are major health concerns with multiple factors, like advanced end glycation products (AGEs), in the background. AGEs induce long-lasting functional modification of the proteins and collagen in the vascular wall and nerve tissue. We investigated the effect of alpha-lipoic acid (ALA) treatment on AGEs, soluble AGE receptor (sRAGE), the AGE/sRAGE ratio, and the parameters of endothelial dysfunction and their correlations. Methods: In our 6-month intervention study, 54 T2DM patients with neuropathy treated according to the actual therapeutic guidelines with unchanged oral antidiabetic drugs were included and treated by daily oral administration of 600 mg ALA. A total of 24 gender and age-matched T2DM patients without neuropathy served as controls. Results: In our work, we first demonstrated the attenuating effect of alpha lipoic acid therapy on AGEs in humans (11.89 (9.44–12.88) to 10.95 (9.81–12.82) AU/μg (p = 0.017)). sRAGE levels or the AGEs/sRAGE ratio were not affected by ALA treatment or by the presence of neuropathy. We found a correlation between the changes of AGEs and the improvement of current perception threshold and progranulin levels, and an inverse correlation with the change of asymmetric dimethylarginine. Conclusions: According to our results, ALA decreases AGEs, which may contribute to the clinically well-known beneficial effect in diabetic neuropathy and improvement of endothelial function.
- Open Access
- 21 October 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (10) , 565
Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto’s Thyroiditis on Levothyroxine Substitution
Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto’s thyroiditis (HT). Methods: Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Results: Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4–148.3) pg/mL vs. 131.9 (44.8–236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Conclusions: Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.
- 21 October 2024
- Published by MDPI AG in Metabolites
- Vol. 14 (10) , 565
Open AccessLow Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto’s Thyroiditis on Levothyroxine Substitution
Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto’s thyroiditis (HT). Methods: Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Results: Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4–148.3) pg/mL vs. 131.9 (44.8–236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Conclusions: Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.
- Open Access
- 9 May 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 396, 111045
Cyclosporin A inhibits PDGF-BB induced hyaluronan synthesis in orbital fibroblasts
- 9 May 2024
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 396, 111045
Open AccessCyclosporin A inhibits PDGF-BB induced hyaluronan synthesis in orbital fibroblasts
- Open Access
Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts; A Potential Pleiotropic Effect in Graves’ Orbitopathy
Orbital connective tissue expansion is a hallmark of Graves’ orbitopathy (GO). In moderate-to-severe active GO, glucocorticoids (GC) are the first line of treatment. Here we show that hydrocortisone (HC), prednisolone (P), methylprednisolone (MP), and dexamethasone (DEX) inhibit the hyaluronan (HA) production of orbital (OF) and dermal (DF) fibroblasts. HA production of GO OFs (n = 4), NON-GO OFs (n = 4) and DFs (n = 4) was measured by ELISA. mRNA expression of enzymes of HA metabolism and fibroblast proliferation was examined by RT-PCR and BrdU incorporation, respectively. After 24 h of GC treatment (1µM) HA production decreased by an average of 67.9 ± 3.11% (p < 0.0001) in all cell cultures. HAS2, HAS3 and HYAL1 expression in OFs also decreased (p = 0.009, p = 0.0005 and p = 0.015, respectively). Ten ng/mL PDGF-BB increased HA production and fibroblast proliferation in all cell lines (p < 0.0001); GC treatment remained effective and reduced HA production under PDGF-BB-stimulated conditions (p < 0.0001). MP and DEX reduced (p < 0.001, p = 0.002, respectively) PDGF-BB-induced HAS2 expression in OFs. MP and DEX treatment decreased PDGF-BB stimulated HAS3 expression (p = 0.035 and p = 0.029, respectively). None of the GCs tested reduced the PDGF-BB stimulated proliferation rate. Our results confirm that GCs directly reduce the HA production of OFs, which may contribute to the beneficial effect of GCs in GO.
Open AccessGlucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts; A Potential Pleiotropic Effect in Graves’ Orbitopathy
Orbital connective tissue expansion is a hallmark of Graves’ orbitopathy (GO). In moderate-to-severe active GO, glucocorticoids (GC) are the first line of treatment. Here we show that hydrocortisone (HC), prednisolone (P), methylprednisolone (MP), and dexamethasone (DEX) inhibit the hyaluronan (HA) production of orbital (OF) and dermal (DF) fibroblasts. HA production of GO OFs (n = 4), NON-GO OFs (n = 4) and DFs (n = 4) was measured by ELISA. mRNA expression of enzymes of HA metabolism and fibroblast proliferation was examined by RT-PCR and BrdU incorporation, respectively. After 24 h of GC treatment (1µM) HA production decreased by an average of 67.9 ± 3.11% (p < 0.0001) in all cell cultures. HAS2, HAS3 and HYAL1 expression in OFs also decreased (p = 0.009, p = 0.0005 and p = 0.015, respectively). Ten ng/mL PDGF-BB increased HA production and fibroblast proliferation in all cell lines (p < 0.0001); GC treatment remained effective and reduced HA production under PDGF-BB-stimulated conditions (p < 0.0001). MP and DEX reduced (p < 0.001, p = 0.002, respectively) PDGF-BB-induced HAS2 expression in OFs. MP and DEX treatment decreased PDGF-BB stimulated HAS3 expression (p = 0.035 and p = 0.029, respectively). None of the GCs tested reduced the PDGF-BB stimulated proliferation rate. Our results confirm that GCs directly reduce the HA production of OFs, which may contribute to the beneficial effect of GCs in GO.
- Open Access
Different Effects of Cigarette Smoke, Heated Tobacco Product and E-Cigarette Vapour on Orbital Fibroblasts in Graves’ Orbitopathy; a Study by Real Time Cell Electronic Sensing
Thyroid autoimmunity in Graves’ disease (GD) is accompanied by Graves’ orbitopathy (GO) in 40% of the cases. Orbital fibroblasts (OF) play a key role in the pathogenesis and cigarette smoking is a known deteriorating factor. Alongside conventional cigarettes (CC) new alternatives became available for smokers, including heated tobacco products (HTP) and E-cigarettes (ECIG). We aimed to study the cellular effects of smoke extracts (SE) in orbital fibroblasts. Primary OF cultures from GO and NON-GO orbits were exposed to different concentrations of SE (1%, 50%) and the changes were followed using Real Time Cell Electronic Sensing (RT-CES). Untreated GO and NON-GO cells had different maximum cell index (CI) values of 3.3 and 2.79 respectively (p < 0.0001). CC, HTP and ECIG treated NON-GO fibroblasts exhibited peak CIs of 2.62, 3.32 and 3.41 while treated GO cells’ CIs were higher, 5.38, 6.25 and 6.33, respectively (p < 0.0001). The metabolic activity (MTT) decreased (p < 0.001) and hyaluronan production doubled (p < 0.02) after 50% of CC SE treatment in all cell cultures. GO fibroblasts were more sensitive to low concentration SE then NON-GO fibroblasts (p < 0.0001). The studied SEs exerted different effects. RT-CES is a sensitive technique to detect the effects of very low concentration of SE on fibroblasts.
Open AccessDifferent Effects of Cigarette Smoke, Heated Tobacco Product and E-Cigarette Vapour on Orbital Fibroblasts in Graves’ Orbitopathy; a Study by Real Time Cell Electronic Sensing
Thyroid autoimmunity in Graves’ disease (GD) is accompanied by Graves’ orbitopathy (GO) in 40% of the cases. Orbital fibroblasts (OF) play a key role in the pathogenesis and cigarette smoking is a known deteriorating factor. Alongside conventional cigarettes (CC) new alternatives became available for smokers, including heated tobacco products (HTP) and E-cigarettes (ECIG). We aimed to study the cellular effects of smoke extracts (SE) in orbital fibroblasts. Primary OF cultures from GO and NON-GO orbits were exposed to different concentrations of SE (1%, 50%) and the changes were followed using Real Time Cell Electronic Sensing (RT-CES). Untreated GO and NON-GO cells had different maximum cell index (CI) values of 3.3 and 2.79 respectively (p < 0.0001). CC, HTP and ECIG treated NON-GO fibroblasts exhibited peak CIs of 2.62, 3.32 and 3.41 while treated GO cells’ CIs were higher, 5.38, 6.25 and 6.33, respectively (p < 0.0001). The metabolic activity (MTT) decreased (p < 0.001) and hyaluronan production doubled (p < 0.02) after 50% of CC SE treatment in all cell cultures. GO fibroblasts were more sensitive to low concentration SE then NON-GO fibroblasts (p < 0.0001). The studied SEs exerted different effects. RT-CES is a sensitive technique to detect the effects of very low concentration of SE on fibroblasts.
- 1 August 2021
- Published by Elsevier in Atherosclerosis
- Vol. 331, e201
Strong correlations between serum fibroblast growth factor 21 level and lipid parameters in patients with autoimmune thyroiditis
- 1 August 2021
- Published by Elsevier in Atherosclerosis
- Vol. 331, e201
Strong correlations between serum fibroblast growth factor 21 level and lipid parameters in patients with autoimmune thyroiditis